This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.64% per year. These returns cover a period from January 1, 1988 through August 4, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
UnitedHealth Group, Inc. is the largest health care services company in the world, serving over 50 million individuals in the United States as of 2019 and over 5 million internationally. The company provides a wide range of health care products and services, such as health maintenance organizations (HMOs), point of service plans (POS), preferred provider organizations (PPOs), and managed fee-for-service programs. UnitedHealth has the largest and most diverse membership base within the managed-care organization market, which gives it significant competitive advantages. It also has built its prescription drug business through OptumRx division, with the acquisition of Catamaran in 2015.
Is CNC Banking on Membership Growth to Boost Scale & Profitability?
by Tanuka De
Centene's growing membership base boosts revenue scale and operational efficiency, even as medical inflation puts pressure on margins.
CVS Advances Digital Efforts to Simplify Healthcare Experience
by Moumi Mondal
CVS Health commits $20B to build an open health platform, joining tech giants in a push to streamline patient care access nationwide.
When 90% Isn't an A+: Elevance's Cost Crunch and Carelon's Cushion
by Kaibalya Pravo Dey
ELV trims 2025 outlook as medical costs climb, but commercial growth and Carelon's momentum aim to steady performance.
Should You Invest in UnitedHealth (UNH) Based on Bullish Wall Street Views?
by Zacks Equity Research
Based on the average brokerage recommendation (ABR), UnitedHealth (UNH) should be added to one's portfolio. Wall Street analysts' overly optimistic recommendations cast doubt on the effectiveness of this highly sought-after metric. So, is the stock worth buying?
Can UnitedHealth Really Fight Cost Headaches With $3.3B Amedisys Pill?
by Kaibalya Pravo Dey
UNH's $3.3B Amedisys deal will likely clear DOJ hurdles with divestitures, aiming to tap fast-growing home healthcare amid rising cost pressures.
When a Healthcare Giant Gets Sick: Elevance Health's 20% YTD Decline
by Kaibalya Pravo Dey
ELV's 20% YTD slump reflects shrinking memberships, rising costs and deepening analyst pessimism despite long-term growth levers.
Is CVS a Smart Buy Now on Strong Q2, Low Valuation & Long-Term Upside?
by Urmimala Biswas
CVS appears well-poised on strong Q2 revenue growth, raised full-year guidance and momentum in key healthcare segments.
One Big Beautiful Bill Act: A Boon or Bane for Centene?
by Tanuka De
CNC faces both risk and reward from the One Big Beautiful Bill Act as Medicaid cuts collide with digital reform gains.
UnitedHealth Crashing After Q2 Shock: Should You Panic or Pounce?
by Kaibalya Pravo Dey
UNH plunges 12.9% after weak Q2 and slashing 2025 EPS guidance, sparking fears of deeper structural issues ahead.
UnitedHealth Group Incorporated (UNH) Is a Trending Stock: Facts to Know Before Betting on It
by Zacks Equity Research
Zacks.com users have recently been watching UnitedHealth (UNH) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
Stock Market News for Jul 30, 2025
by Zacks Equity Research
Wall Street closed lower on Tuesday, pulled down by industrial and discretionary stocks.
UnitedHealth Q2 Earnings Miss Estimates on Increasing Medical Costs
by Zacks Equity Research
UNH misses Q2 earnings estimates as surging medical costs slash EPS 40%, despite revenue growth and Optum Rx strength.
Trade Deficit Comes in Lower Than Expected
by Zacks Equity Research
Trade Deficit Comes in Lower Than Expected.
Pre-Markets Up Again on Big News Morning
by Mark Vickery
From a vast array of earnings reports to key economic prints to a massive railway merger likely to pass its government board, it's been a busy morning.
Here's What Key Metrics Tell Us About UnitedHealth (UNH) Q2 Earnings
by Zacks Equity Research
Although the revenue and EPS for UnitedHealth (UNH) give a sense of how its business performed in the quarter ended June 2025, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
UnitedHealth Group (UNH) Q2 Earnings Lag Estimates
by Zacks Equity Research
UnitedHealth (UNH) delivered earnings and revenue surprises of -15.70% and +0.06%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
S&P 500 & Nasdaq Notch New All-Time Closing Highs
by Mark Vickery
Markets lost a bit of steam mid-session this Monday, but a late surge into the close brought the S&P 500 and the Nasdaq indexes to new record closing highs.
Can Optum Support UnitedHealth's Profit Amid Industry Headwinds?
by Zacks Equity Research
UNH leans on Optum's diversified growth and value-based care to counter insurance sector margin pressure in Q2.
Is It Worth Investing in UnitedHealth (UNH) Based on Wall Street's Bullish Views?
by Zacks Equity Research
According to the average brokerage recommendation (ABR), one should invest in UnitedHealth (UNH). It is debatable whether this highly sought-after metric is effective because Wall Street analysts' recommendations tend to be overly optimistic. Would it be worth investing in the stock?
CVS or UnitedHealth: Which Stock Is a Better Buy Ahead of Q2 Earnings?
by Urmimala Biswas
CVS shows resilience with stable insurance margins and capital discipline, while UNH faces cost headwinds and a sharp earnings cut.
UnitedHealthcare Pressure Builds: Trouble Ahead for UNH's Q2 Earnings?
by Kaibalya Pravo Dey
UNH braces for a steep Q2 profit drop as soaring medical costs and DOJ scrutiny shake investor confidence.
Medical Expenses Erode Centene's Bottom Line in Rare Q2 Earnings Miss
by Zacks Equity Research
CNC reports rare Q2 loss amid surging medical costs, lower investment and other income despite strong revenue growth.
Centene (CNC) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Centene (CNC) delivered earnings and revenue surprises of -123.53% and +10.93%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
UnitedHealth Group (UNH) Stock Sinks As Market Gains: Here's Why
by Zacks Equity Research
In the closing of the recent trading day, UnitedHealth Group (UNH) stood at $278.58, denoting a -4.76% move from the preceding trading day.
UnitedHealth on Thin Ice Before Q2 Earnings: Should Investors Exit?
by Kaibalya Pravo Dey
UNH braces for a 27% earnings drop in Q2 as soaring medical costs, margin pressure and investor jitters weigh on performance.